PepGen PEPG 深 滬
已收盤 08-07 16:00:00 美东时间
2.85
+0.440
+18.26%
華盛通- 最 高2.875
- 今 開2.48
- 成交量 322.40万股
- 最 低 2.44
- 昨 收 2.41
- 總市值 1.97亿
- 52周最高 7.80
- 市盈率 靜 --
- 換手率 4.66%
- 52周最低 1.13
- 委 比 -7.78%
- 總股本 6916.92万
- 歷史最高 20.00
- 量 比 2.62
- 振 幅 18.05%
- 歷史最低 0.8801
- 每 手 1
- 風險率 1.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PepGen Q2 EPS $(0.26) Beats $(0.29) Estimate
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 62.86 percent increase over losses of $(0.70) per share from the same period last year.
08-06 20:04
Kalaris Appoints Laurie Keating to Board of Directors
Kalaris Therapeutics announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. Keating brings extensive expertise in biotechnology, having previously served in senior roles at Alnylam Pharmaceuticals and Millennium Pharmaceuticals. Her addition is expected to support Kalaris' growth and development of treatments for retinal diseases, including the ongoing clinical trial for TH103, a potential therapy for con...
07-06 20:05
美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级
今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元
06-17 11:32
Craig-Hallum Initiates Coverage On PepGen with Buy Rating, Announces Price Target of $11
Craig-Hallum analyst Adam Vogel initiates coverage on PepGen (NASDAQ:PEPG) with a Buy rating and announces Price Target of $11.
06-16 22:33
PepGen To Highlight Data From PGN-EDODM1 Program In Poster And Late-Breaking Oral Presentation At IDMC-15
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases,
05-21 19:04
PepGen Files Prospectus To Offer Up To $400M Of Common Stock
https://www.sec.gov/Archives/edgar/data/1835597/000119312526228960/d132482ds3.htm
05-20 00:09
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Wedbush Maintains Outperform on PepGen, Lowers Price Target to $4
Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price target from $5 to $4.
05-13 22:41
PepGen Q1 EPS $(0.26) Beats $(0.31) Estimate
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 71.74 percent increase over losses of $(0.92) per share from the same
05-13 05:06
Top 3 Health Care Stocks Which Could Blast Off This Quarter
Undervalued companies in health care sector with low RSI values present buying opportunity: PepGen Inc (PEPG), KALA BIO Inc (KALA), Viridian Therapeutics Inc (VRDN)
04-08 18:40
